Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ketamine + midazolam + ketamine + propofol
- Development stage
- Phase 4
- Lead developer
- University of Alexandria
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
The name 'ketamine + midazolam + ketamine + propofol' refers to the pharmacological components of two distinct sedation regimens compared in a randomized, single-blind clinical trial (NCT06368219) conducted by Alexandria University. The study evaluates the efficacy and safety of combining ketamine (a dissociative anesthetic and NMDA receptor antagonist) with either midazolam (a benzodiazepine and GABA-A receptor positive allosteric modulator) or propofol (a sedative-hypnotic and GABA-A receptor modulator) for procedural sedation in adult emergency department patients. These combinations, often colloquially referred to as 'keta-mid' and 'ketofol', are used to provide analgesia and sedation while potentially minimizing the adverse effects associated with higher doses of the individual agents. The trial specifically compares the incidence of complications between these two regimens in an emergency setting.
- Other names
- Ketamine-Midazolam vs Ketamine-PropofolKetamine + MidazolamKetamine + Propofol
02
Targets
GABRR (GABA-A receptor subunit rho)NMDAR (Glutamate receptor ionotropic, NMDA)
Beyond the preview
Go deeper on ketamine + midazolam + ketamine + propofol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ketamine + midazolam + ketamine + propofol.